Novartis announced that the Tekturna labels have been updated in the USA, following the FDA review of the preliminary findings...
Tekturna/Rasilez (aliskiren) from Novartis has failed to show a benefit in target organ protection which has resulted in the early...
The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...
Following the closure of the Phase III ALTITUDE trial, researchers have published the first detailed figures showing the risk of...
Sevikar HCT (olmesartan medoxomil, amlodipine besylate plus hydrochlorothiazide) from Daiichi Sankyo Europe, the first three-in-one pill to treat Hypertension, has...
The US patent on Diovan (valsartan) and the combination product Diovan HCT (valsartan plus the diuretic hydrochlorothiazide) from Novartis has...
ANI Pharmaceuticals, Inc. announced that it has acquired the NDAs and U.S. rights to market Atacand, Atacand HCT, Arimidex, and...